非結核分枝桿菌（NTM）：市場展望、流行病學、競爭格局和市場預測報告，2025-2035年

市場概覽

• 預計德國非結核分枝桿菌市場將經歷溫和成長，這得益於診斷技術的進步和標靶治療的日益普及，市場規模將從 2025 年的 1.04 億美元成長到 2035 年的 1.32 億美元。
• 以下因素正在影響市場擴張：
• 吸入式脂質體療法和專門治療方法。
• 對非結核分枝桿菌感染疾病的認知和診斷水準提高
• 儘管患者數量成長緩慢（年均複合成長率為 0.7%），但由於治療週期長、治療費用高，市場規模得以維持。
• 未來的成長取決於開發更有效、耐受性更好的治療方法，以縮短治療時間並提高治癒率。

非結核分枝桿菌（NTM）概述

非結核分枝桿菌（NTM）肺病是由環境分枝桿菌引起的慢性進行性性呼吸道感染，最常見的是鳥分枝桿菌複合群（MAC）和膿腫分枝桿菌。此疾病主要影響已有肺部結構性疾病的患者，例如支氣管擴張、囊腫纖維化和慢性阻塞性肺病（COPD），這些疾病會因氣道清除功能受損而加劇持續感染疾病。

病理學，非結核分枝桿菌（NTM）感染會導致慢性肉芽腫性炎症，進而引起進行性性肺損傷、纖維化和肺功能下降。診斷較為複雜，需結合臨床症狀、特徵性影像學觀察（例如，高解析度CT（HRCT）上的結節或空洞性病變）以及微生物學檢查結果。

由於非結核分枝桿菌（NTM）固有的抗生素抗藥性和生物膜形成能力，治療NTM極具挑戰性。目前的標準治療方案是合併多種抗生素療法，通常以大環內酯類抗生素為主，在細菌培養轉陰後至少持續用藥12個月。然而，這些治療方法有許多挑戰，包括顯著的毒性、耐受性差以及較高的治療失敗率和復發率。為了克服這些局限性，治療模式已發展為標靶治療，例如吸入脂質體Aminoglycosides，這種藥物可在肺部達到高濃度，同時最大限度地減少全身暴露。儘管取得了這些進展，NTM仍然是一種難以治療的疾病，仍有巨大的未滿足醫療需求。

主要亮點

• 在德國，預計確診病例數將從 2025 年的 4,400 例增加到 2035 年的 4,700 例，成長幅度適中（年複合成長率為 0.7%）。
• 治療過程仍然漫長而複雜，毒性高，藥物依從性低，且復發頻繁，凸顯了巨大的未滿足醫療需求。
• 隨著人們對吸入療法和新型抗分枝桿菌藥物的關注度不斷提高，治療效果有望得到改善，疾病管理也將改變。

格式化和更新訊息

• 詳細報告（PDF）
• 市場預測模型（基於微軟Excel）
• 流行病學數據（MS Excel，互動式工具）
• 高階主管洞察（PPT簡報）
• 其他功能：定期更新、自訂和顧問支援。
• 根據 Thelansis 的政策，我們確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

• 如何最佳化 G8 市場（美國、歐盟 5 國、日本、中國）的藥物開發與生命週期管理策略？
• 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
• 未來十年市場收入和病患佔有率的預測是多少？
• 哪些因素對市場趨勢影響最大？
• 受訪專家對目前和新興的治療方法有何看法？
• 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
• 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
• 為確保藥物核准並順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

• G8
  • 美國
  • EU5
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國
  • 日本
  • 中國

大公司

• Novartis Pharmaceuticals

目錄

第1章：主要調查結果及分析師說明

• 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章：疾病背景

• 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章：流行病學

• 重點
• 發病率/盛行率
• 已確診並接受藥物治療的患者人數
• 合併症
• 其他相關患者群

第4章 市場規模及預測

• 重點
• 市場促進因素與限制因素
• 按藥物類別分類的趨勢
• 各國具體趨勢

第5章 競爭情勢

• 目前的治療方法
• 重點
• 診斷和治療過程/演算法
• 主要治療方法概述及KOL洞察
• 新興治療方法
• 重點
• 值得關注的後期新治療方法－概述、市場上市預期及KOL洞察
• 值得關注的早期研發管線

第6章：未滿足的需求與目標產品分析

• 主要未滿足的需求以及透過新興治療方法實現的未來可能性
• TPP分析與KOL展望

第7章 監理與報銷環境

第8章附錄

Non-Tuberculous Mycobacterial (NTM) Market Outlook

Thelansis's "Non-Tuberculous Mycobacterial (NTM) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Non-Tuberculous Mycobacterial treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Non-Tuberculous Mycobacterial (NTM) Overview

Non-Tuberculous Mycobacterial (NTM) pulmonary disease is a chronic, progressive respiratory infection caused by environmental mycobacteria, most commonly Mycobacterium avium complex (MAC) and Mycobacterium abscessus. The disease primarily affects individuals with pre-existing structural lung conditions such as bronchiectasis, cystic fibrosis, and Chronic Obstructive Pulmonary Disease, where impaired airway clearance facilitates persistent infection.

Pathophysiologically, NTM infection drives chronic granulomatous inflammation, leading to progressive lung damage, fibrosis, and functional decline. Diagnosis is complex and requires a combination of clinical symptoms, characteristic radiological findings (e.g., nodular or cavitary lesions on HRCT), and microbiological confirmation.

Treatment is highly challenging due to intrinsic antibiotic resistance and biofilm formation. The current standard of care involves prolonged, multidrug antibiotic regimens-typically macrolide-based-administered for >=12 months post-culture conversion. However, these regimens are associated with significant toxicity, poor tolerability, and high rates of treatment failure or relapse. To address these limitations, the treatment paradigm has evolved toward targeted approaches, including inhaled liposomal aminoglycosides, which enable high local drug concentrations in the lungs while minimizing systemic exposure. Despite these advances, NTM remains a difficult-to-treat condition with substantial unmet need.

Key Highlights

• In Germany, the diagnosed patient pool is projected to increase from 4.4K in 2025 to 4.7K by 2035, reflecting modest growth (0.7% CAGR).
• Treatment remains prolonged and complex, with high rates of toxicity, poor adherence, and frequent relapse, underscoring significant unmet clinical need.
• Increasing focus on inhaled therapies and novel anti-mycobacterial agents is expected to improve treatment outcomes and reshape disease management.

Market Overview

• The Germany NTM market is projected to grow from $104M in 2025 to $132M by 2035, reflecting moderate growth driven by improved diagnosis and adoption of targeted therapies.
• Market expansion is influenced by:
• Uptake of inhaled liposomal therapies and specialized regimens
• Increasing recognition and diagnosis of NTM infections
• Despite modest patient growth (0.7% CAGR), market value is supported by long treatment durations and high-cost therapies.
• Future growth will depend on the development of more effective, better-tolerated therapies that reduce treatment duration and improve cure rates.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Novartis Pharmaceuticals

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)